Welcome to touchPODCAST where you can listen and learn from our expert faculty, hand-picked from the Touch Medical Media family of independent medical websites. Educating physicians on a fully global scale since 2005! We make positive changes to clinical practice, with the ultimate objective of improving patient and community health. Working alongside leading medical experts, societies and industry, our mission is to provide practical, expert opinions to support best practices for busy Healthcare Professionals globally, by translating published data into easily digestible and timely updates Home of: - touchONCOLOGY - touchENDOCRINOLOGY - touchOPHTHALMOLOGY - touchNEUROLOGY - touchCARDIOLOGY - touchINFECTIOUSDISEASES - touchIMMUNOLOGY - touchRESPIRATORY - touchHAEMATOLOGY - touchDERMATOLOGY This information is intended for use by licensed Healthcare Professionals (HCPs). It should not be considered medical advice, diagnosis, or treatment recommendations.
Episodes
Tuesday Jul 20, 2021
Tuesday Jul 20, 2021
touchMDT for touchENDOCRINOLOGY
Listen to key experts from a multidisciplinary team consider the unmet needs in patients at high risk of ASCVD and how novel lipid-lowering therapies may help
The multidisciplinary team
- Endocrinologist: Professor Lawrence Leiter, Canada
- Cardiologist: Dr Constantine Kosmas, USA
This touchPODCAST is for HCPs only.
This activity is funded by an unrestricted independent medical education grant from Novartis Pharma AG, Basel, Switzerland. This activity is jointly provided by USF Health and touchIME.
For further information visit our website:
https://touchendocrinologyime.org/novel-lipid-lowering-therapies-for-reducing-ascvd-risk/
Tuesday Jul 20, 2021
Tuesday Jul 20, 2021
touchMDT for touchENDOCRINOLOGY
Listen to key experts from a multidisciplinary team discuss the risk factors and lipoproteins associated with ASCVD and guideline recommendations for the management of patients with dyslipidemia
The multidisciplinary team
- Cardiologist: Dr Constantine Kosmas, USA
- Primary care physician: Dr Yassir Javaid, UK
This touchPODCAST is for HCPs only.
This activity is funded by an unrestricted independent medical education grant from Novartis Pharma AG, Basel, Switzerland. This medical education is provided by touchIME.
Tuesday Jul 20, 2021
Tuesday Jul 20, 2021
touchMDT for touchCARDIO
Listen to key experts from a multidisciplinary team consider the latest data for novel lipid-lowering therapies and what they may mean for their patients with dyslipidaemia
The multidisciplinary team
- Primary care physician: Dr Yassir Javaid, UK
- Cardiologist: Dr Constantine Kosmas, USA
- Endocrinologist: Professor Lawrence Leiter, Canada
This touchPODCAST is for HCPs only.
This activity is funded by an unrestricted independent medical education grant from Novartis Pharma AG, Basel, Switzerland. This medical education is provided by touchIME.
For further information visit our website: https://touchcardioime.org/novel-lipid-lowering-therapies-for-reducing-ascvd-risk//
Tuesday Jul 20, 2021
Tuesday Jul 20, 2021
touchMDT for touchCARDIO
Listen to key experts from a multidisciplinary team consider the unmet needs in patients at high risk of ASCVD and how novel lipid-lowering therapies may help
The multidisciplinary team
- Endocrinologist: Professor Lawrence Leiter, Canada
- Cardiologist: Dr Constantine Kosmas, USA
This touchPODCAST is for HCPs only.
This activity is funded by an unrestricted independent medical education grant from Novartis Pharma AG, Basel, Switzerland. This medical education is provided by touchIME.
For further information visit our website: https://touchcardioime.org/novel-lipid-lowering-therapies-for-reducing-ascvd-risk//
Tuesday Jul 20, 2021
Tuesday Jul 20, 2021
touchMDT for touchCARDIO
Listen to key experts from a multidisciplinary team discuss the risk factors and lipoproteins associated with ASCVD and guideline recommendations for the management of patients with dyslipidemia.
The multidisciplinary team
- Cardiologist: Dr Constantine Kosmas, USA
- Primary care physician: Dr Yassir Javaid, UK
This touchPODCAST is for HCPs only.
This activity is funded by an unrestricted independent medical education grant from Novartis Pharma AG, Basel, Switzerland. This medical education is provided by touchIME.
For further information visit our website: https://touchcardioime.org/novel-lipid-lowering-therapies-for-reducing-ascvd-risk//
Wednesday Jun 30, 2021
Wednesday Jun 30, 2021
touchEXPERT OPINIONS for touchONCOLOGY
Listen to leading experts in breast cancer share their opinion on the latest data which may help guide the use of CDK4/6 inhibitors in HR+/HER2- advanced breast cancer.
The experts
- Dr Luca Malorni - Hospital of Prato, Italy
- Prof. Aleix Prat - Hospital Clínic Barcelona, Spain
- Dr Barbara Pistilli - Gustave Roussy, Villejuif, France
This touchPODCAST is for HCPs only.
This activity is funded by an unrestricted independent medical education grant from Novartis and is provided by touchIME.
For further information visit our website: https://touchoncology.com/education/cdk-inhibitors-breast-cancer/
Monday Apr 26, 2021
Monday Apr 26, 2021
touchPANEL DISCUSSION for touchIMMUNOLOGY
Listen to a panel of experts discuss using biologics to optimize outcomes for patients with type 2 asthma and how biomarkers can inform treatment decisions.
The experts
- Dr Michael Wechsler - National Jewish Health and University of Colorado, Denver, USA
- Dr Roland Buhl - Mainz University Hospital, Mainz, Germany
- Dr Flavia Hoyte - National Jewish Health and University of Colorado, Denver, USA
This touchPODCAST is for HCPs only.
This activity is funded by an unrestricted independent medical education grant from Sanofi Genzyme and Regeneron Pharmaceuticals. This activity is provided by touchIME.
For further information visit our website: https://touchimmunologyime.org/pd-in-disease-control-in-moderate-to-severe-type-2-asthma/
Thursday Apr 22, 2021
Thursday Apr 22, 2021
touchPANEL DISCUSSION for touchRESPIRATORY
Listen to a panel of experts discuss using biologics to optimize outcomes for patients with type 2 asthma and how biomarkers can inform treatment decisions.
The experts
- Dr Michael Wechsler - National Jewish Health and University of Colorado, Denver, USA
- Dr Roland Buhl - Mainz University Hospital, Mainz, Germany
- Dr Flavia Hoyte - National Jewish Health and University of Colorado, Denver, USA
This touchPODCAST is for HCPs only.
This activity is funded by an unrestricted independent medical education grant from Sanofi Genzyme and Regeneron Pharmaceuticals. This activity is provided by touchIME.
For further information visit our website: https://touchrespiratoryime.org/pd-in-disease-control-in-moderate-to-severe-type-2-asthma/
Wednesday Mar 17, 2021
Wednesday Mar 17, 2021
touchCONGRESS for touchIMMUNOLOGY
Walter Maksymowych (University of Alberta, Alberta, Canada) talks to touchIMMUNOLOGY about the results of the C-axSpAnd Study (NCT02552212). This 52-week placebo-controlled study aimed to identify demographic or baseline characteristics of patients with nr-axSpA that could be predictive of achieving a clinical response to treatment with certolizumab pegol.
The abstract entitled ‘Predictors of Response in Patients with Non-Radiographic Axial Spondyloarthritis Receiving Certolizumab Pegol in the C-axSpAnd Study’ was presented at ACR Convergence 2020, 5-9 November.
Tuesday Mar 09, 2021
Tuesday Mar 09, 2021
touchEXPERT OPINIONS for touchONCOLOGY
Listen to leading experts discuss how monoclonal antibody (MAb) biosimilars for solid tumours are developed and approved, and learn about the practical aspects of their use in oncology pharmacy.
The experts
- Dr Paul Cornes - Comparative Outcomes Group, Bristol, UK
- Dr Joseph Bubalo - Oregon Health & Science University Hospital & Clinics, Portland, USA
- Mr Hisanaga Nomura - Japan Agency for Medical Research and Development, Tokyo, Japan
This touchPODCAST is for HCPs only.
This activity is funded by an unrestricted independent medical educational grant from Pfizer. This activity is provided by touchIME.
For further information visit our website: https://touchoncology.com/education/mab-biosimilars-in-the-treatment-of-solid-tumours-perspectives-for-pharmacists/